Lombard Medical Technologies Share Discussion Threads

[shorewalk] 03/10/2013 08:28

Turnover vs no. of units sold calculates at approx. £10000 per unit. Could be wildly inaccurate, but I suspect not that far out. Actual operation probably over £100000, so sorry wealthy nations only. Hence the companies calculation of the value of the market based on nos. needing it. Increased screening in west will identify more people needing preventative surgery ie. Aorfix. If the Abdominal Aorta ruptures basically you've had it - so if identified you'd get it 'fixed' regardless of cost.

[rayrac] 03/10/2013 07:29

Is it only wealthy nations who can afford Aorfix? Or is it because aneurysms don't occur in poor nations?

How much does one Aorfix fix, cost, anyone know?

[nod] 02/10/2013 21:20

Year on year patient numbers in H1 were almost the same - 194 patients - revenues are more variable because of stocking. Germany and Spain were very good but it's not clear whether that was product stocking or increase in patients. Germany up 47%My understanding is that Aorfix is not yet approved in Japan.The lacklustre country was the UK and that was due to changes in purchasing but may not have affected actual patient use (this is not clear). Overall progress has been positive and it seems probable that significant sales will come in the USA and Germany and eventually Japan and other wealthy nations. It has been a long haul getting to this point.

[bbluesky] 02/10/2013 17:59

If the US start using it and the RNS suggests that they will, then I think it will become a global standard and the lacklustre European take-up will start to take off and Japan and and and. Major move ahead imo.

[philo124] 02/10/2013 17:51

Still here.

[rayrac] 02/10/2013 17:07

I get the impression that not many have got their eye on the ball here Skinny.

[skinny] 02/10/2013 14:07

Well done on your addition Rayrac - I'd rather taken my eye off of the ball here.

[rayrac] 02/10/2013 14:03

One thing is absolutely certain in my mind. LMT will not remain single for very long. There's no point to its existence, other than being part of a much larger prey.

[rayrac] 02/10/2013 11:15

That's their choice Nod. We all have that, but not always forced on us.

I'm afraid it's the plus side I'm looking at!

It's strange that the share price moved a day or so before today's rns. Leaky?

[rayrac] 02/10/2013 11:11

Yes balcony, I topped up with 10k this am.

[skinny] 02/10/2013 10:33

The last update was on September 4th :-

Canaccord Genuity Buy 187.00 243.00 256.00 Reiterates

[callumross] 02/10/2013 10:12

25k buy just gone through.Sure someone said the broker target price is around 260p but can't remember the exact figure

[nod] 02/10/2013 10:12

The sale looks good although it is paid in four instalments over four years end 2014 to end 2017. So we only see funds if the business survives and can afford to pay us.R&D staff have to relocate to a much more expensive part of the country.

[balcony] 02/10/2013 10:09

Rayrac-We got great news in my opinion at 10am this morning,i notice on another BB that you say you have a placed a order here

[rayrac] 02/10/2013 10:02

Sp perking up! Worth a punt on some news soon?

[skinny] 02/10/2013 09:31

London, UK and Irvine, CA, 2 October 2013 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focused on innovative vascular products, today announces that due to increasing demand for its lead product, Aorfix, the Company is expanding its facility in Didcot, Oxfordshire and has taken a strategic decision to divest its non-core OEM business based in Prestwick, Scotland. The R&D and process development activities for Aorfix currently undertaken at the Prestwick facility will be transferred to the expanded R&D and manufacturing facilities in Didcot. The Company will continue to run the OEM business until 20 December 2013, the completion date of the transaction.

The Company is seeing growing demand for Aorfix in the US following receipt of US FDA approval earlier this year; is experiencing growing sales in Europe; and anticipates regulatory approval for Aorfix in Japan in H1 2014. Aorfix is the Company's uniquely labeled stent graft device for the treatment of AAAs ("Abdominal Aortic Aneurysms") with neck angulations up to 90 degrees. To meet the increasing demand for Aorfix, the Company is expanding its facilities in Didcot by around 10,000 sqft., involving the construction of a new cleanroom and materials handling space, at a cost of around £0.3m. The expansion is expected to be completed in the first quarter of 2014 and new jobs will be created at the site once the new facility is operational.

The OEM business, which manufactures a range of medical products for third parties, and certain assets, will be divested to Culzean Medical Devices Limited for £0.6m in cash. The consideration is receivable in four annual instalments from the end of 2014 and will be used for general working capital purposes. The book value of the assets to be disposed of was less than £0.1m as at 31 December 2012; and in the year ended 31 December 2012, the OEM business generated a profit before tax of £0.1m (after the recharge of central costs) on revenue of £0.7m. OEM revenue in the first half of 2013 was £0.3m and is expected to show a decline in the full year.

Under the terms of the divestment agreement, some employees in Scotland will transfer to support the new owner's business activities; other employees will be given the opportunity to relocate to Didcot.


-Ends-

[orange1] 02/10/2013 09:29

Today's announcement reads very well: divestment of non-core business at a good price, expansion of core business in Didcot. I wonder how many staff will choose to relocate from Prestwick to Didcot.

[callumross] 02/10/2013 08:39

Seems to be real positive momentum building on this one now.

[nod] 28/9/2013 22:39

Compared with other Options and Share Incentive Schemes I've seen recently this looks to be very fair and reasonable. The exercise price is close to the current price and not well below it. Without being specific the conditions appear to be linked to revenue performance unlike some other companies where they avoid revenue targets. In summary, the options appear to be aligned with shareholders which is exemplary.

[shorewalk] 26/9/2013 17:45

Options for new Chairman as predicted. Would like to know the performance criteria - would give a fair exit/co.sale expectation. Expect an update on sales of system/new patients prior to the official US launch and probably a steady share price rise. IMHO

[rayrac] 24/9/2013 13:30

Maybe nows the time ?

[nod] 07/9/2013 03:58

The target of 256p is 55% higher than where we are.It's interesting that Canaccord should not just reiterate Buy but raises the target it had set around 15 July of 243pWhat do they know?

[orange1] 05/9/2013 06:14

Would make more sense if it read 2.5% rather than 25% maybe.